We are live on ! Find out more
SCPS

Scopus BioPharma Inc. Common Stock
SCPS

Delisted

SCPS was delisted on the 16th of December, 2022.

Back to rankings

17 hedge funds and large institutions have $293K invested in Scopus BioPharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

11% less funds holding

Funds holding: 19 → 17 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

58% less capital invested

Capital invested by funds: $693K → $293K (-$400K)

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$27.9K
2
TRCT
Tower Research Capital (TRC)
New York
+$9.12K
3
Renaissance Technologies
Renaissance Technologies
New York
+$8.81K
4
Goldman Sachs
Goldman Sachs
New York
+$8.36K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$6.38K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$149K
2
BlackRock
BlackRock
New York
-$25K
3
VF
Virtu Financial
New York
-$21K
4
BCM
Bridgeway Capital Management
Texas
-$16.8K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$93K +$6.38K +13,273 +7%
Renaissance Technologies
2
Renaissance Technologies
New York
$56K +$8.81K +18,329 +16%
MRCM
3
M&R Capital Management
New Jersey
$33K – – –
HF
4
HRT Financial
New York
$25K +$27.9K +58,162 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$24K -$149K -309,792 -85%
BCM
6
Bridgeway Capital Management
Texas
$14K -$16.8K -35,000 -51%
TRCT
7
Tower Research Capital (TRC)
New York
$12K +$9.12K +18,971 +206%
First Manhattan
8
First Manhattan
New York
$11K – – –
State Street
9
State Street
Massachusetts
$9K – – –
Goldman Sachs
10
Goldman Sachs
New York
$7K +$8.36K +17,405 New
Northern Trust
11
Northern Trust
Illinois
$5K – – –
CLOS
12
Compagnie Lombard Odier SCmA
Switzerland
$2K – – –
JP Morgan Chase
13
JP Morgan Chase
New York
$2K – – –
BlackRock
14
BlackRock
New York
– -$25K -36,675 Closed
VF
15
Virtu Financial
New York
– -$21K -30,229 Closed
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$14K -20,723 Closed
MC
17
Moors & Cabot
Massachusetts
– -$10K -14,500 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$1K -2,109 Closed
Wells Fargo
19
Wells Fargo
California
– +$3 +7 +9%
HI
20
Harbour Investments
Wisconsin
– +$481 +1,000 New

SCPS Hedge Fund Activity: Q2 2022 in Review

17 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q2 2022, worth a combined $293K — down 58% from $693K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of SCPS and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $27.9K. The largest seller was Vanguard Group, cutting an estimated $149K.

  • 17 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q2 2022, down from 19 in Q1 2022.
  • Funds reported $293K of Scopus BioPharma Inc. Common Stock stock for Q2 2022, down 58% quarter-over-quarter.
  • 3 funds opened new Scopus BioPharma Inc. Common Stock positions in Q2 2022 and 5 closed out, a net change of -2 holders.
  • The largest Scopus BioPharma Inc. Common Stock buyer in Q2 2022 was HRT Financial, an estimated $27.9K added.
  • The largest Scopus BioPharma Inc. Common Stock seller in Q2 2022 was Vanguard Group, an estimated $149K sold.

Based on aggregated 13F filings for Q2 2022.